Roche comes up short in its attempt to hold off generic competition to Esbriet
Roche’s blockbuster idiopathic pulmonary fibrosis drug Esbriet brings in more than $1 billion a year — and the Swiss pharma giant would like to keep it that way. Too bad a Delaware federal judge doesn’t agree.
US District Judge Richard Andrews ruled on Tuesday that Novartis’ Sandoz unit didn’t infringe on Roche’s patents with its submission of abbreviated NDAs (ANDAs) for its pirfenidone generic tablets, and found that some of those patent claims are invalid due to “obviousness.”
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.